BPC-157 sublingual tablets · 500 mcg / tablet (60-tablet supply)- ·60 × 500 mcg tablets in sealed blister
BPC-157 oral (60 × 500 mcg tablets)
Oral / sublingual tablet presentation — 60 tablets × 500 mcg.
Oral tablet presentation of BPC-157. The Sikirić literature notes stability of BPC-157 in gastric juice; this format enables oral-route research protocols.
What the peptide is.
The Sikirić group has reported that BPC-157 is stable in human gastric juice over extended periods — a finding frequently cited as support for oral-route research. The 60-tablet supply covers extended in vitro absorption-research protocols.
Oral bioavailability data for BPC-157 is sparse in the published literature. The format is provided for researchers specifically investigating oral-route work.
Same as the 15 mg injectable presentation.
Reconstitution, storage, and handling.
Lab-technical guidance for the researcher handling the material. Not therapeutic dosing, not administration guidance — those are not within the scope of this supply.
- Recommended solvent
- N/A — tablets
- Typical volume
- N/A
- Tablets are sealed in foil blister; store as-received.
- Lyophilised
- Room temperature, dry, sealed. Avoid direct light.
- Reconstituted
- N/A
- Shelf life · sealed
- 24 months sealed at room temperature.
- Shelf life · reconstituted
- N/A
- ▸Blister-sealed tablets. Single-lot for the 60-tablet supply.
This lot, documented.
Every shipment is accompanied by a signed four-page analytical report including the HPLC chromatogram, ESI-MS spectrum, purity calculation, and sample handling chain-of-custody.
The report you will receive is specific to the lot dispatched to you. The display below is a current representative example.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
REPORT ID JA-26-04-012
SUBJECT BPC-157 oral (60 × 500 mcg tablets)
DESIGNATION BPC-157 sublingual tablets
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.40
MASS EXP. 1419.55 Da
MASS OBS. 1419.57 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11Research references for BPC-157 oral (60 × 500 mcg tablets).
1 peer-reviewed publications. Links resolve to PubMed. DOIs are provided where available.
- [01]Sikirić P, et al.
BPC 157 — gastric juice stability
Current Pharmaceutical Design · 2013
- Q.Is oral BPC-157 bioavailable?
- A.The gastric stability of BPC-157 has been reported. Absorption and systemic bioavailability are active research questions with limited published human data.
This peptide is supplied by Omega Grade for in vitro laboratory research use. It is not a drug, food, cosmetic, or dietary supplement. It is not approved by the FDA, EMA, MHRA, PMDA, or any other regulatory authority for any therapeutic indication.
No claim of therapeutic benefit is made or implied. The material is not intended for human or veterinary consumption, administration, or any form of self-experimentation. By purchasing, you acknowledge the researcher terms and accept full responsibility for local import compliance and all handling.
Often considered alongside.
BPC-157 15 mg
Pentadecapeptide — 15-residue fragment of a gastric body-protection protein.
- Form
- Lyophilised kit
- Dose
- 15 mg / vial
- Purity
- ≥ 99.4%
BPC-157 + TB-500 10/10 mg kit
Paired regenerative peptides — combined kit, most-requested blend.
- Form
- Lyophilised kit
- Dose
- 10 mg BPC-157 + 10 mg TB-500 / vial
- Purity
- ≥ 99.0% (both peptides)